Semaglutide

Product Details

Introduction Somaglutide is a new generation of GLP-1 (Glucagon-like peptide-1) analog developed by Danmano and NovoNordisk. Somaglutide is a long-term dosage form developed based on the basic structure of Liraglutide, which has better effect in treating type 2 diabetes. Novo Nordisk has completed six PhaseIIIa studies on Somaglutide injection, and submitted a new drug registration application for Somaglutide injection once a week to the Food and Drug Administration (FDA) on December 5, 2016, as well as a marketing authorization application (MAA) to the European Medicines Agency (EMA). On the other hand, the daily oral preparation of Somaglutide is currently in clinical phase III. Action Somaglutide is a long-term dosage form developed based on the basic structure of Liraglutide, which has better effect in the treatment of type 2 diabetes. The preparation adopts solid-liquid phase synthesis method to prepare somalutide. The straight chain peptide Aib8, Arg34GLP-1 (7-37) and fat side chain acylating agent were prepared by Solid-phase synthesis. The straight chain peptide Lys26 was modified with the synthetic fat chain acylating agent under alkaline conditions to obtain Somaglutide, and the biological activity of the self prepared samples was determined by time-resolved Förster resonance energy transfer immunoassay. Semegglutide, a new GLP-1 receptor agonist, is a novel GLP-1 analogue that is injected subcutaneously once a week. Somaglutide is a long-acting GLP-1 analog developed by Novo Nordisk for subcutaneous injection once per week. Compared with Liraglutide, Somaglutide has a longer fat chain and increased hydrophobicity, but Somaglutide is modified by short chain PEG, and its hydrophilicity is greatly enhanced. After PEG modification, it can not only closely combine with albumin, cover up the site of DPP-4 Enzymatic hydrolysis, but also reduce renal excretion, extend the Biological half-life, and achieve the effect of long circulation. Novo Nordisk's Somaglutide hanged Sitagliptin of DPP-4, and GLP-1's originator long-acting exenatide (it should be designed to compete head to head with Lilly's trustiness, and bullying has been in the market for a long time). In the experiment, high-dose Soma reduced A1C1.6%, with a maximum weight loss of 6kg. Somaglutide was tested in 813 patients with 2Chemicalbook type diabetes to investigate the efficacy and safety of 1.0mg Somaglutide compared with 2.0mg Exenatide injected once a week. The test period was 56 weeks, and the patients took 1-2 anti diabetes drugs orally at the same time.